PBAC's latest decision on Aflibercept: Recommended (2025). Considered for Treatment of subfoveal choroidal neovascularisation (CNV) due to pathologic myopia (PM) in adults.
PBAC outcome
Recommended
Authority Required
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
15
first 2012
PBS spend
$414M
423,776 scripts · 2024
Eligible population
Adults with subfoveal choroidal neovascularisation due to pathologic myopia.
Therapy area
Ophthalmology
Line of therapy
Any
Evidence base
Cost-minimisation
Primary endpoint
Cost-minimisation
Comparator
Eylea (reference biologic aflibercept)
Economic model
Cost-minimisation
ICER note
Cost-minimisation analysis; no ICER calculated. Eydenzelt is a biosimilar with no expected net cost to PBS as it substitutes for Eylea.
ICER (historical)
$45k/QALY–$75k/QALY across 3 submissions (2013–2014) — the latest submission carried no numeric base case. No single PSD states this combined range; see source PSDs.
PBS expenditure
The Australian government paid $414M in PBS benefits for Aflibercept in 2024 across 423,776 scripts, at $977 per script.
Submission history
Mar 2012: Recommended with restriction · Authority Required
Jul 2013: Not recommended · Authority Required — ICER $75k/QALY
Jul 2013: Not recommended · Authority Required — ICER $70k/QALY
Mar 2014: Recommended with restriction · Authority Required — ICER $75k/QALY
Nov 2014: Recommended with restriction · Authority Required
Nov 2014: Recommended with restriction · Authority Required
Mar 2015: Recommended · Authority Required
Nov 2015: Recommended with restriction · Authority Required
Jul 2019: Recommended with restriction · Restricted
May 2024: Recommended with restriction · Authority Required
May 2024: Recommended with restriction · Authority Required
Nov 2024: Recommended with restriction · Authority Required
Nov 2024: Recommended with restriction · Authority Required